The most common (> 20%) adverse reactions, including laboratory abnormalities, with Larotrectinib were increased AST, increased ALT, anemia musculoskeletal pain, fatigue, hypoalbuminemia, neutropenia, increased alkaline phosphatase, cough, leukopenia, constipation, diarrhea, dizziness, hypocalcemia, nausea, vomiting, pyrexia, lymphopenia, and abdominal pain.
from FDA,2022.11
The tropomyosin receptor kinase (TRK) fusion protein produced by the fusion of t···【more】
Release date:2024-11-19Recommended:119